Solvay Announces Strategic Collaboration With Ginkgo Bioworks And Expands Its R&I Footprint In The United States

The investment will accelerate the development of new sustainable biopolymers, strengthening Solvay's position in biotechnology in this important growth platform.

BRUSSELS and BOSTON, April 4, 2023 /PRNewswire/ -- Solvay, a leading science and materials company whose technologies bring benefits to many aspects of daily life, today announced a strategic collaboration with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. Through this multi-year strategic collaboration agreement, Solvay will join forces with Ginkgo to unlock the power of synthetic biology as an enabler of more sustainable chemicals and materials, contributing to the transition towards more environmentally-friendly solutions. This alliance will start by focusing on new sustainable biopolymers, specialties which could tangibly impact a breadth of markets, from home and personal care to agriculture and food.

As part of this partnership, Solvay will also acquire a Ginkgo (formerly Zymergen) laboratory in Cambridge, Massachusetts. This acquisition will expand Solvay's research and innovation (R&I) footprint in the US, provide Solvay access to new talents, and establish a sustainable growth base in synthetic biology in one the most important biotech hubs in the world, accelerating the company's biotech development plan.

With this strategic collaboration and expansion, Solvay will integrate deep competencies in bioinformatics and data science, strain engineering, biocatalysis and fermentation processes, strengthening and accelerating the ability to scout, develop and turn into businesses the most valuable biotech-enabled opportunities.

This partnership is designed to strengthen Solvay's position in biotechnology as part of the Renewable Materials and Biotechnology growth platform which aims to meet growing demand for sustainable solutions by increasing the share of renewable carbon in Solvay's product offering and developing new business opportunities enabled by biotechnology. This growth platform complements the company's activities in three other key areas: battery materials, green hydrogen and thermoplastic composites.

"We're thrilled to make this important investment and to partner with Ginkgo Bioworks on an exciting project to develop sustainable chemicals and materials, allowing us to provide innovative biotechnologies to new markets," said Solvay CEO Ilham Kadri. "Biotech is the future and this step is an important milestone for our growth platform. We expect to leverage our new presence in the Boston area to step up and accelerate our offerings in this field."

"We're so excited to welcome Solvay to our platform and to the Boston area at such a pivotal growth period for both of our companies. In our case, it's fantastic to be able to integrate platform capabilities from Zymergen and make them accessible to our partners so quickly" said Jason Kelly, CEO and co-founder of Ginkgo Bioworks, "Synthetic biology can help companies across a wide breadth of markets reach their environmental and economic goals at the same time, and it's thrilling to work with a partner taking such a big swing at sustainability."

About Solvay

Solvay is a science company whose technologies bring benefits to many aspects of daily life. With more than 22,000 employees in 61 countries, Solvay bonds people, ideas and elements to reinvent progress. Solvay seeks to create sustainable shared value for all, notably through its Solvay One Planet roadmap crafted around three pillars: protecting the climate, preserving resources and fostering a better life. The Group's innovative solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices, health care applications, water and air purification systems. Founded in 1863, Solvay today ranks among the world's top three companies for the vast majority of its activities and delivered net sales of €13.4 billion in 2022. Solvay is listed on Euronext Brussels and Paris (SOLB). Learn more at www.solvay.com.

About Solvay's Renewable Materials and Biotechnology platform

This investment is a key part of Solvay's Renewable Materials and Biotechnology growth platform strategy. The platform focuses on developing innovative and sustainable solutions using renewable feedstocks and biotechnology. It aims to meet growing demand for sustainable solutions by increasing the share of sustainable renewable carbon in Solvay's product offering and developing new business opportunities enabled by biotechnology. The platform's ambition relies on a holistic innovation approach with three interconnected pillars: sustainable renewable carbon, biotechnology and end-of-life management. It follows the establishment of the Group's growth platforms in batteries, green hydrogen and thermoplastic composites.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as Twitter (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), or LinkedIn. 

Forward-Looking Statements of Ginkgo Bioworks

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customer. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 13, 2023 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

GINKGO BIOWORKS INVESTOR CONTACT:
[email protected]

GINKGO BIOWORKS MEDIA CONTACT:
[email protected]

SOLVAY MEDIA RELATIONS
Solvay Investor relations
Laetitia Van Minnenbruggen
+32 484 65 30 47

Kim Jordan
+1 346 268 2677

[email protected]

SOLVAY INVESTOR RELATIONS
Jodi Allen
+1 609 860 4608

Geoffroy d'Oultremont
+32 2 264 2997

Bisser Alexandrov
+32 2 264 3687

Valérie-Anne Barriat
+32 476 841 177

Alex Sokolowski
+32 2 264 1168

[email protected]

SOURCE Ginkgo Bioworks